Recommendations for probiotic use-2015 update proceedings and consensus opinion

Journal of Clinical Gastroenterology

Volumn 49, Issue , 2015, Pages S69-S73

  Floch, Martin H ^a   Walker, W Allan ^b,c   Sanders, Mary Ellen ^e   Nieuwdorp, Max ^g,h   Kim, Adam S ⁱ   Brenner, David A ^f   Qamar, Amir A ^d   Miloh, Tamir A ^j,k,l   Guarino, Alfredo ^m   Guslandi, Mario ⁿ   Dieleman, Levinus A ^o   Ringel, Yehuda ^p   Quigley, Eamonn M M ^q,r   Brandt, Lawrence J ^s  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ Minnesota Gastroenterology PA   (United States)

^j PHOENIX CHILDREN'S HOSPITAL   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o UNIVERSITY OF ALBERTA   (Canada)

^p UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^q HOUSTON METHODIST HOSPITAL   (United States)

^r WEILL CORNELL MEDICAL COLLEGE   (United States)

^s ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ACUTE GASTROENTERITIS; ALLERGY; ATOPY; BIFIDOBACTERIUM INFANTIS; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYSTIC FIBROSIS; DIARRHEA; DYSBIOSIS; ENERGY EXPENDITURE; FAMILIAL HYPERCHOLESTEROLEMIA; FECES MICROFLORA; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; LIVER DISEASE; LIVER FAILURE; METABOLIC DISORDER; NECROTIZING ENTEROCOLITIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ADULT; CHILD; CONSENSUS DEVELOPMENT; ENTEROCOLITIS, NECROTIZING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; IRRITABLE BOWEL SYNDROME; LIVER DISEASES; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; STANDARDS;

ADULT; CHILD; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, NECROTIZING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; IRRITABLE BOWEL SYNDROME; LIVER DISEASES; PROBIOTICS;

EID: 84944191475     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000420     Document Type: Review

References (64)

1. Sanders ME. Probiotics in 2015; their scope and use. J Clin Gastroenterol. 2015;49(suppl):S2-S6.
2. Houghteling PD, Walker WA. From birth to "immunohealth", allergies and enterocolitis. J Clin Gastroenterol. 2015;49(suppl):S7-S12.
3. Bakker GJ, Zhao J, Herrema H, et al. Gut microbiota and energy expenditure in health and obesity. J Clin Gastroenterol. 2015;49(suppl):S13-S19.
4. Kim A. Dysbiosis; a review highlighting obesity and inflammatory bowel disease. J Clin Gastroenterol. 2015;49(suppl):S20-S24.
5. Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-214.
6. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-484.
7. Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
8. Brenner DA, Paik Y-H, Schnabl B. Role of gut microbiota in liver disease. J Clin Gastroenterol. 2015;49(suppl):S25-S27.
9. Qamar AA. Probiotics in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis. J Clin Gastroenterol. 2015;49(suppl):S28-S32.
10. Mittal VV, Sharma BC, Sharma P, et al. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011;23:725-732.
11. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an openlabel randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol. 2012;107:1043-1050.
12. Shukla S, Shukla A, Mehboob S, et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Alimen Pharmacol Ther. 2011;33:662-671.
13. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotics on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-1095.
14. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotics VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-543.
15. Wai-Sun Wong V, Lai-Hung Wong G, Mei-Ling Chim A, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12:256-262.
16. Malaguarnera M, Vacane M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2012;57:545-553.
17. Miloh T. Probiotics in pediatric liver disease. J Clin Gastroenterol. 2015;49(suppl):S33-S36.
18. Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2015;49(suppl):S37-S45.
19. Guslandi M. Role of probiotics in Crohn's disease and in pouchitis. J Clin Gastroenterol. 2015;49(suppl):S46-S49.
20. Chibbar R, Dieleman LA. Probiotics in the management of ulcerative colitis. J Clin Gastroenterol. 2015;49(suppl):S50-S55.
21. Ringel Y, Ringel-Kulka T. The intestinal microbiota and irritable bowel syndrome. J Clin Gastroenterol. 2015;49(suppl):S56-S59.
22. Quigley EMM. Probiotics in irritable bowel syndrome; the science and the evidence. J Clin Gastroenterol. 2015;49(suppl):S60-S64.
23. Brandt LJ. Fecal microbiota transplant; respice, adspice, prospice. J Clin Gastroenterol. 2015;49(suppl):S65-S68.
24. Louie T, Cannon K, O'grady H, et al. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). Presented at ID week, 201389. October 3, 2013. Los Angeles, CA.
25. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;31:1772-1778.
26. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol. 2011;45:S168-S171.
27. Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidencebased guidelines for the management of acute gastroenteritis in children in Europe update 2014. J Pediatr Gastroenterol Nutr. 2014;59:132-152.
28. Szajewska H, Guarino A, Hojsak I, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58:531-539.
29. Szajewska HJ, Skórka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhea in children. Aliment Pharmacol Ther. 2007;25:257-264.
30. Szajewska H, Urbańska M, Chmielewska A, et al. Metaanalysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children. Benef Microbes. 2014;5:285-293.
31. Surawicz CM. Role of probiotics in antibiotic associated diarrhea, Clostridium difficile associated diarrhea and recurrent Clostridium difficile diarrhea. J Clin Gastroenterol. 2008;42:S64-S70.
32. Doron S, Hibberd P, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol. 2008;42:S58-S63.
33. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ. 2007;355:80.
34. Na X, Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol. 2011;45:S154-S158.
35. Evidence-based medicine. Available at: http://en. wikipedia.org/wiki/Evidence-based-medicine. Accessed June 26, 2011.
36. Brandt LJ, Reddy SS. Fecal microbiotic transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol. 2011;45:S159-S167.
37. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol. 2006;40:249-255.
38. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
39. Gionchetti P, Rizzello F, Helwig U, et al. Prophylactis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology. 2003;124:1202-1209.
40. Mimura T, Rizzello F, Helwig U, et al. Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
41. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-2084.
42. Rembacken FJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet. 1999;354:635-639.
43. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
44. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443.
45. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
46. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease. J Clin Gastroenterol. 1997;25:653-658.
47. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464.
48. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457.
49. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590.
50. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome (IB): symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551.
51. Kim JH, Camilleri M, McKenzie S, et al. A randomized controlled trial of a probiotic, VSL#3 on gut transit and symptoms in diarrhea-predominant IBS. Aliment Pharmacol Ther. 2003;17:895-904.
52. Kim JH, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating. Neurogastroenterol Motil. 2005;17:687-696.
53. Guandalini S, Magazzu G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: an international, randomized, placebo-controlled, double-blinded, cross-over study. J Pediatr Gastroenterol Nutr. 2010;51:24-30.
54. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-172 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475-486.
55. Niedzielin K, Kordecki H, Birkenfeld B, et al. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147.
56. Ganguli K, Walker WA. Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol. 2011;45:S133-S138.
57. Lin HC, Chyong-Hsin H, Hsiu-Lin C, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth rate preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122:693-700.
58. Isolauri E, Joensuu J, Suomalainen H, et al. Improved immunogenicity of oral DxRRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310-312.
59. Isolauri E, Salminen S. Probiotics: use in allergic disorders. J Clin Gastroenterol. 2008;42:S91-S96.
60. Delia P, Sansotta G, Donato V, et al. Prevention of radiationinduced diarrhea with the use of VLS#3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002;97:2150-2152.
61. Salminen E, Eloman I, Minkkinen J, et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988;39:435-437.
62. Hilton F, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candida vaginitis. Am Intern Med. 1992;116:353-357.
63. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8:2772-2776.
64. Anukam KC, Osazuwu E, Osemen GI, et al. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006;8:2772-2776.